| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CTSO |
| Uniprot No | P43234 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 108-321aa |
| 氨基酸序列 | LPLRFDWRDKQVVTQVRNQQMCGGCWAFSVVGAVESAYAIKGKPLEDLSVQQVIDCSYNNYGCNGGSTLNALNWLNKMQVKLVKDSEYPFKAQNGLCHYFSGSHSGFSIKGYSAYDFSDQEDEMAKALLTFGPLVVIVDAVSWQDYLGGIIQHHCSSGEANHAVLITGFDKTGSTPYWIVRNSWGSSWGVDGYAHVKMGSNVCGIADSVSSIFV |
| 预测分子量 | 28.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与CTSO(假设为Cathepsin O或相关抗原)重组蛋白相关的参考文献示例：
1. **《重组人CTSO蛋白在大肠杆菌中的高效表达及纯化》**
- 作者：Zhang L. 等人
- 摘要：本研究通过构建pET载体在大肠杆菌中表达可溶性CTSO重组蛋白，采用镍柱亲和层析纯化，获得高纯度蛋白，为后续功能研究奠定基础。
2. **《CTSO重组蛋白的酶活性分析及其在肿瘤侵袭中的作用》**
- 作者：Wang Y. 等人
- 摘要：通过体外实验证实CTSO重组蛋白具有特异性蛋白酶活性，并发现其通过降解细胞外基质促进乳腺癌细胞迁移，提示其作为治疗靶点的潜力。
3. **《基于CTSO重组蛋白的多克隆抗体制备及临床应用评估》**
- 作者：Chen H. 等人
- 摘要：利用纯化的CTSO重组蛋白免疫家兔获得多克隆抗体，ELISA和免疫组化显示其在卵巢癌组织中高表达，可能成为新型诊断标志物。
注：以上文献为示例性内容，实际引用需根据具体研究方向检索PubMed或SciHub等数据库获取真实论文。若CTSO指向特定抗原(如癌症睾丸抗原家族)，建议结合精确关键词(如“CTSO recombinant protein cancer”)进行文献筛选。
**Background of CTSO Recombinant Protein**
Recombinant proteins, engineered through genetic modification, are pivotal in modern biotechnology and medicine. CTSO (Cancer-Testis Specific Antigen) recombinant protein is a synthetic version of a protein naturally expressed in germline cells (e.g., testes) but often aberrantly activated in cancer cells. This unique expression pattern classifies CTSO as a cancer-testis antigen (CTA), a group of proteins explored as targets for cancer immunotherapy due to their restricted presence in healthy tissues and widespread expression in malignancies.
CTSO’s role in cancer biology remains under investigation, but its immunogenic properties make it a candidate for therapeutic strategies. Recombinant CTSO is typically produced by inserting the *CTSO* gene into expression vectors (e.g., bacterial, yeast, or mammalian systems), followed by purification via chromatography. This ensures high specificity and scalability, addressing limitations of native protein extraction.
In research, recombinant CTSO aids in studying tumor antigen presentation, immune response activation, and mechanisms of immune evasion. Clinically, it is investigated for vaccine development, where it may stimulate T-cells to target CTSO-expressing tumors. Additionally, it serves as a tool for antibody production, enabling diagnostic assays or targeted therapies.
Challenges include optimizing protein folding and post-translational modifications (e.g., glycosylation) to mimic native structures, critical for functional studies. Advances in expression systems (e.g., mammalian cell lines) and purification techniques continue to enhance CTSO’s applicability.
Overall, CTSO recombinant protein represents a bridge between cancer biology and immunotherapy innovation, with potential to improve personalized oncology treatments by leveraging the immune system against tumor-specific antigens. Ongoing research aims to validate its efficacy and safety in preclinical and clinical settings.
×
